

# **AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA377)**

## **NICE GUIDANCE ISSUED JANUARY 2016**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

### **Final Appraisal Recommendation**

**Advice No: 1415 – July 2015**

### **Enzalutamide (Xtandi<sup>®</sup>▼) 40 mg soft capsules**

#### **Submission by Astellas Pharma Ltd**

#### **Recommendation of AWMSG**

**Enzalutamide (Xtandi<sup>®</sup>▼) is recommended as an option for use within NHS Wales for the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.**

**This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised.**

#### **Additional note(s):**

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1773), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review every three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1415:  
Enzalutamide (Xtandi<sup>®</sup>▼) 40 mg soft capsules. July 2015.

